As the new cover story of Nature Biomedical Engineering, the CRISPR-Chip technology from our Innovation partner Nanosens Innovations Inc.showcases a great example of how Cardea’s graphene biosensors can be used to create innovative and first-of-a-kind life-science products.
As the new cover story of Nature Biomedical Engineering, the CRISPR-Chip technology from our Innovation partner Nanosens Innovations Inc.showcases a great example of how Cardea’s graphene biosensors can be used to create innovative and first-of-a-kind life-science products.
“Especially the CRISPR-Chip’s unrivaled time-to-result and no-need-of-a-lab feature makes many people very excited about this new way of getting genetics insight.” says Dr. Brett Goldsmith, CTO of Cardea.
The news about the CRISPR-Chip have already broken the Nature Biomedical Engineering “most-read article” record only a few weeks after it had its release online. The CRISPR-Chip peer-reviewed article titled “Detection of Unamplified Target Genes via CRISPR–Cas9 Immobilized on a Graphene Field-Effect Transistor” shows how CRISPR can scan through a human genome, looking for a gene with a specific gene mutation in a clinical sample - in just 15 minutes.
At Cardea we find that this new generation of genetics technology that allows for real-time insight to biology is both practical and mind blowing at the same time. Dr. Kiana Aran’s (co-founder of Nanosens and corresponding author on the publication) fundamental idea and development of this technology allows us to see CRISPR at work in a way we had never imagined before. This is possible as the CRISPR protein complex itself has been carefully integrated with the Cardea biosensor’s graphene, and that way it has become possible to link up CRISPR with Cardea’s an advantaged IT hardware and software infrastructure.
When CRISPR finds the relevant sequence of DNA in the whole genome, it binds its gRNA (the search query) to the ssDNA “target sight”, creating a charge that is detectable by the electrical field of the graphene, that makes up the core of the biosensor.
An independent research group from Laboratory for Sensors, Department of Microsystems Engineering (IMTEK), University of Freiburg in Germany was asked by Nature BME to give their independent perspectives on the CRISPR-chip in the June issue.
Quoting that Nature News and Views article: “In view of the growing demand for portable devices for molecular diagnostics, future versions of the CRISPR-chip might offer an easy-to-handle, versatile and rapid on-chip solution for genome-based diagnostics”.
Furthermore, the Nature BME editorial (by Pep Pàmies, Chief Editor) points out the CRISPR-chip and its “Clever chip designs…” is going to be key if we want to have breakthroughs for diagnostics (incl. (human, plant, animal, bacteria, virus).
The Chief Editor says: “Steady innovations in the design of channels, valves, pumps, sensors and microelectronics, in microchips and in the materials and manufacturing processes for them, will increasingly make them better for diagnostic applications.”
Having worked on graphene biosensor manufacturing and applications for more than five years, we at Cardea strongly agree with that perspective.
For people that will like access to the CRISPR-chip and the Cardea graphene biosensor technologies there is a sign up page atwww.cardeabio.com/partnership
In case of journalists interested in interviews with Dr. Kiana Aran, Dr. Brett Goldsmith or other teams, feel free to contact Amanda Zimmer (azimmer@cardeabio.com), Cardea’s Marketing Associate.
Contacts
Media Contact:
Amanda Zimmer, Marketing Associate
Cardea Bio Inc.
azimmer@cardeabio.com
+1 619 762 1142
Cardea Innovation Partnership Requests:
Rob Lozuk, Director of Partnership Program
Cardea Bio Inc.
IPP@Cardeabio.com
+1 619 762 1142